Cargando…
Nursing Management of Gastrointestinal Adverse Events Associated With Delayed-Release Dimethyl Fumarate: A Global Delphi Approach
BACKGROUND: Gastrointestinal (GI) adverse events (AEs) are commonly encountered with delayed-release dimethyl fumarate (DMF), an approved treatment for relapsing multiple sclerosis (MS). METHODS: Two hundred thirty-nine MS nurses from 7 countries were asked to complete a 2-round Delphi survey develo...
Autores principales: | Campbell, Trudy L., Lefaux, Béatrice Jenny, Mayer, Lori Lee, Namey, Marie, Riemer, Gisela, Robles-Sanchez, Miguel A., White, Sarah, Edwards, Michael, Minor, Charles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069393/ https://www.ncbi.nlm.nih.gov/pubmed/32068560 http://dx.doi.org/10.1097/JNN.0000000000000495 |
Ejemplares similares
-
Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study
por: Theodore Phillips, J., et al.
Publicado: (2015) -
Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study
por: Arnold, Douglas L., et al.
Publicado: (2014) -
Dimethyl fumarate for ischemic stroke
por: Kunze, Reiner
Publicado: (2017) -
Real-world use of dimethyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus
por: Burlando, Martina, et al.
Publicado: (2022) -
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study
por: Arnold, Douglas L., et al.
Publicado: (2014)